Archive for December 2013
A Semi-Mechanistic Modeling approach to support Phase III dose selection for TAK-875 Integrating Glucose and HbA1c Data
Stringer F., Matsuno K., Snelder N. and Hirayama M., A Semi-Mechanistic Modeling approach to support Phase III dose selection for TAK-875 Integrating Glucose and HbA1c Data in Japanese Type 2 Diabetes Patients. PAGE.(2013) [Link to publication]
Read MoreA population PK-PD model for effects of Sipoglitazar on FPG and HbA1c in patients with type II diabetes
Stringer F., DeJongh J., Scott G. and Danhof M., A population PK-PD model for effects of Sipoglitazar on FPG and HbA1c in patients with type II diabetes. PAGE.(2013) [Link to publication]
Read MoreTowards the prediction of cardiovascular effects in human
Snelder N., Ploeger B., Luttringer O., Rigel D., Fu F., Beil M., Stanski D. and Danhof M., Towards the prediction of cardiovascular effects in human. PAGE.(2013) [Link to publication]
Read MorePopulation modeling of blood pressure: assessing clinically important factors for cardiovascular diseases.
Ackaert O., Population modeling of blood pressure: assessing clinically important factors for cardiovascular diseases. Leiden Pharma Science Symposium.(2013)
Read MoreA systems pharmacology model of the APP processing pathway in Alzheimer’s Disease
Maanen E.v., Steeg T.v., Ahsman M., Savage M.J., Michener M.S., Kleijn H.J., Danhof M. and Stone J., A systems pharmacology model of the APP processing pathway in Alzheimer’s Disease. ACoP.(2013) [Link to publication]
Read MoreDevelopment of a dosing regimen for recombinant human antithrombin (rhAT) in pregnant patients
DeJongh J., Frieling J., Lowry S., Drenth H. and Finch M., Development of a dosing regimen for recombinant human antithrombin (rhAT) in pregnant patients. 60th Annual Meeting of the Society for Gynecologic Investigation (SGI) (2013) [Link to publication]
Read MoreA Phase 2 Safety and Tolerability Study to Investigate the Effect of AZD5213 on Sleep
Hannesdottir K., Minkwitz M., Raudibaugh K., Vis P., Ackaert O. and Alexander R. A Phase 2 Safety and Tolerability Study to Investigate the Effect of AZD5213 on Sleep in Subjects with Mild Cognitive Impairment and Mild Alzheimer’s Disease. AAIC (2013)
Read MoreGap identification as a critical step to enable integrated clinical trial simulation platforms
Maanen E.v., deJongh J. and Vis P., Gap identification as a critical step to enable integrated clinical trial simulation platforms; application to TB. joint Critical Path, FDA en ISoP meeting.(2013)
Read MoreCap identification as a critical step to enable integrated clinical trial simultaion platforms
Maanen E.v., deJongh J. and Vis P., Cap identification as a critical step to enable integrated clinical trial simultaion platforms; Application to TB. Critical PAth for Tuberculosis Research Workshop.(2013)
Read MorePharmacokinetic-Pharmacodynamic Modeling of the Antihypertensive Effect of Eprosartan
van Rijn-Bikker P.C., Ackaert O., Snelder N., van Hest R.M., Ploeger B.A., Koopmans R.P. and Mathot R.A., Pharmacokinetic-Pharmacodynamic Modeling of the Antihypertensive Effect of Eprosartan in Black and White Hypertensive Patients, Clin Pharmacokinet, 22: 22, 2013. [Link to publication]
Read More